✦ LIBER ✦

High-dose intravenous immunoglobulin therapy for myasthenia gravis

✍ Scribed by J. L. M. Jongen; P. A. van Doorn; Frans G. A. van der Meché

Publisher: Springer
Year: 1997
Tongue: English
Weight: 39 KB
Volume: 245
Category: Article
ISSN: 0340-5354
DOI: 10.1007/s004150050170

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose intravenous immunoglobulin in

High-dose intravenous immunoglobulin in myasthenia gravis

✍ A. Evoli; M. T. Palmisani; E. Bartoccioni; L. Padua; P. Tonali 📂 Article 📅 1993 🏛 Springer Milan 🌐 English ⚖ 341 KB

High-dose intravenous gamma-globulin the

High-dose intravenous gamma-globulin therapy for myasthenia gravis

✍ I. Bonaventura Ibars; J. Ponseti; T. Español; J. Matias-Guiu; A. Codina-Puiggros 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 90 KB

High-dose intravenous immunoglobulin G t

High-dose intravenous immunoglobulin G treatment of myasthenia gravis

✍ B. Ferrero; L. Durelli 📂 Article 📅 2002 🏛 Springer Milan 🌐 English ⚖ 184 KB

Clinical trial of plasma exchange and hi

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

✍ Dr Philippe Gajdos; Sylvie Chevret; Bernard Clair; Christine Tranchant; Claude C 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 686 KB

Aseptic meningitis as a complication of

Aseptic meningitis as a complication of intravenous immunoglobulin therapy for myasthenia gravis

✍ Ronald J. Ellis; Michael R. Swenson; Joseph Bajorek 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

Randomized, controlled trial of intraven

Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

✍ Gil I. Wolfe; Richard J. Barohn; Barbara M. Foster; Carlayne E. Jackson; John T. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

## Abstract We initiated a randomized, double‐blinded, placebo‐controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in